These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 12611456)
21. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients. Takamura Y; Miyoshi Y; Taguchi T; Noguchi S Cancer; 2001 Jul; 92(2):232-9. PubMed ID: 11466674 [TBL] [Abstract][Full Text] [Related]
22. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380 [TBL] [Abstract][Full Text] [Related]
23. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer]. Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823 [TBL] [Abstract][Full Text] [Related]
24. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. Margeli M; Cirauqui B; Castella E; Tapia G; Costa C; Gimenez-Capitan A; Barnadas A; Sanchez Ronco M; Benlloch S; Taron M; Rosell R PLoS One; 2010 Mar; 5(3):e9499. PubMed ID: 20209131 [TBL] [Abstract][Full Text] [Related]
25. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533 [TBL] [Abstract][Full Text] [Related]
26. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Lips EH; Mulder L; Hannemann J; Laddach N; Vrancken Peeters MTFD; van de Vijver MJ; Wesseling J; Nederlof PM; Rodenhuis S Ann Oncol; 2011 Apr; 22(4):870-876. PubMed ID: 20937646 [TBL] [Abstract][Full Text] [Related]
27. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769 [TBL] [Abstract][Full Text] [Related]
28. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440 [TBL] [Abstract][Full Text] [Related]
29. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436 [TBL] [Abstract][Full Text] [Related]
30. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment. Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830 [TBL] [Abstract][Full Text] [Related]
31. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers. Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S; Cancer Lett; 2008 Jun; 264(1):44-53. PubMed ID: 18280644 [TBL] [Abstract][Full Text] [Related]
33. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988 [TBL] [Abstract][Full Text] [Related]
34. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397 [TBL] [Abstract][Full Text] [Related]
35. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ; Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946 [TBL] [Abstract][Full Text] [Related]
36. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer]. Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284 [TBL] [Abstract][Full Text] [Related]
37. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993 [TBL] [Abstract][Full Text] [Related]
38. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Petit T; Borel C; Ghnassia JP; Rodier JF; Escande A; Mors R; Haegelé P Clin Cancer Res; 2001 Jun; 7(6):1577-81. PubMed ID: 11410493 [TBL] [Abstract][Full Text] [Related]
39. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687 [TBL] [Abstract][Full Text] [Related]
40. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Fernández-Sánchez M; Gamboa-Dominguez A; Uribe N; García-Ulloa AC; Flores-Estrada D; Candelaria M; Arrieta O Med Oncol; 2006; 23(2):171-83. PubMed ID: 16720917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]